EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Gut microbiota and irritable bowel syndrome

Ye Zhao, Duo Wu Zou iD

Journal of Digestive Diseases · 2023-05 · 24 (5) · 312-320

DOI: 10.1111/1751-2980.13204 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Digestive Diseases, online erschienen am 04.08.2023. Verfasst von Ye Zhao und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Gastrointestinal Microbiome. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 92 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Irritable bowel syndrome (IBS) is a common gastrointestinal disorder that poses a significant health concern. Although its etiology remains unknown, there is growing evidence that gut dysbiosis is involved in the development and exacerbation of IBS. Previous studies have reported altered microbial diversity, abundance, and composition in IBS patients when compared to controls. However, whether dysbiosis or aberrant changes in the intestinal microbiota can be used as a hallmark of IBS remains inconclusive. We reviewed the literatures on changes in and roles of intestinal microbiota in relation to IBS and discussed various gut microbiota manipulation strategies. Gut microbiota may affect IBS development by regulating the mucosal immune system, brain–gut–microbiome interaction, and intestinal barrier function. The advent of high‐throughput multi‐omics provides important insights into the pathogenesis of IBS and promotes the development of individualized treatment for IBS. Despite advances in currently available microbiota‐directed therapies, large‐scale, well‐organized, and long‐term randomized controlled trials are highly warranted to assess their clinical effects. Overall, gut microbiota alterations play a critical role in the pathophysiology of IBS, and modulation of microbiota has a significant therapeutic potential that requires to be further verified.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Irritable Bowel SyndromeGastrointestinal MicrobiomeHumansDysbiosisDefecation

Stichwörter der Autor:innen

dysbiosisgastrointestinal microbiomeirritable bowel syndromemicrobiota manipulation strategy

Autor:innen und Institutionen

  • Department of Gastroenterology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

ORCID-Profile: Duo Wu Zou

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhao, Y., & Zou, D. W. (2023). Gut microbiota and irritable bowel syndrome. Journal of Digestive Diseases, 24(5), 312-320. https://doi.org/10.1111/1751-2980.13204

Vancouver

Zhao Y, Zou DW. Gut microbiota and irritable bowel syndrome. Journal of Digestive Diseases. 2023;24(5):312-320. doi:10.1111/1751-2980.13204

BibTeX
@article{Zhao2023,
  author = {Zhao, Ye and Zou, Duo Wu},
  title = {Gut microbiota and irritable bowel syndrome},
  journal = {Journal of Digestive Diseases},
  year = {2023},
  volume = {24},
  number = {5},
  pages = {312--320},
  doi = {10.1111/1751-2980.13204}
}
Kostenlos starten →